Torvinen S - Search Results

1

Regulation Awareness and Experience of Additional Monitoring among Healthcare Professionals in Finland.

Sandberg A, Ehlers P, Torvinen S, Sandberg H, Sivén M. Sandberg A, et al. Among authors: torvinen s. Healthcare (Basel). 2021 Nov 11;9(11):1540. doi: 10.3390/healthcare9111540. Healthcare (Basel). 2021. PMID: 34828586 Free PMC article.

2

Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.

Mankinen P, Vihervaara V, Torvinen S, Martikainen J, Soini E. Mankinen P, et al. Among authors: torvinen s. J Med Econ. 2019 Apr;22(4):328-335. doi: 10.1080/13696998.2019.1569457. Epub 2019 Feb 4. J Med Econ. 2019. PMID: 30644325 Free article.

3

Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab.

Ylisaukko-Oja T, Torvinen S, Ventola H, Schmidt S, Herrala S, Kononoff J, Voutilainen M. Ylisaukko-Oja T, et al. Among authors: torvinen s. Scand J Gastroenterol. 2019 Jun;54(6):726-732. doi: 10.1080/00365521.2019.1627579. Epub 2019 Jun 16. Scand J Gastroenterol. 2019. PMID: 31203693

4

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. Ylisaukko-Oja T, et al. Among authors: torvinen s. Biologicals. 2019 Mar;58:50-56. doi: 10.1016/j.biologicals.2019.01.007. Epub 2019 Feb 10. Biologicals. 2019. PMID: 30755369 Clinical Trial.

5

Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.

Ylisaukko-Oja T, Puttonen M, Jokelainen J, Koivusalo M, Tamminen K, Torvinen S, Voutilainen M. Ylisaukko-Oja T, et al. Among authors: torvinen s. Scand J Gastroenterol. 2022 Apr;57(4):415-423. doi: 10.1080/00365521.2021.2014950. Epub 2021 Dec 19. Scand J Gastroenterol. 2022. PMID: 34927504

6

Färkkilä N, Torvinen S, Roine RP, Sintonen H, Hänninen J, Taari K, Saarto T. Färkkilä N, et al. Among authors: torvinen s. Qual Life Res. 2014 May;23(4):1387-94. doi: 10.1007/s11136-013-0562-y. Epub 2013 Nov 1. Qual Life Res. 2014. PMID: 24178630

7

Costs of colorectal cancer in different states of the disease.

Färkkilä N, Torvinen S, Sintonen H, Saarto T, Järvinen H, Hänninen J, Taari K, Roine RP. Färkkilä N, et al. Among authors: torvinen s. Acta Oncol. 2015 Apr;54(4):454-62. doi: 10.3109/0284186X.2014.985797. Epub 2014 Dec 18. Acta Oncol. 2015. PMID: 25519708

8

Costs in different states of prostate cancer.

Torvinen S, Färkkilä N, Roine RP, Sintonen H, Saarto T, Taari K. Torvinen S, et al. Acta Oncol. 2016;55(1):30-7. doi: 10.3109/0284186X.2015.1030037. Epub 2015 Apr 2. Acta Oncol. 2016. PMID: 25833414

9

Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise.

Torvinen S, Nieminen P, Lehtinen M, Paavonen J, Demarteau N, Hahl J. Torvinen S, et al. J Med Econ. 2010;13(2):284-94. doi: 10.3111/13696998.2010.485951. J Med Econ. 2010. PMID: 20482244 Free article.

10

Bergius S, Torvinen S, Muhonen T, Roine RP, Sintonen H, Taari K. Bergius S, et al. Among authors: torvinen s. Scand J Urol. 2017 Feb;51(1):13-19. doi: 10.1080/21681805.2016.1247293. Epub 2016 Nov 4. Scand J Urol. 2017. PMID: 27809631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page